University of Iowa Research Foundation

University of California

Other

Chiron Corporation

Wyeth Holdings Corporation

Bradford W Gibson

Michael A Apicella

Melvin G Sunshine

Na-Gyong Lee

Rasappa Arumugham

Nancy J Phillips

Marcus Aaron Horwitz

Irwin D Kuntz

Eric W Taylor

Lawrence D Horwitz

Gavin D Dollinger

Jennifer L Edwards

Malin Young

Connie M Oshiro

Maria Fortuna-Nevin

Karoline Scheffler

Ning Tang

Nicole M Samuels

Judith C Hempel

Paul A Jones

Simon Allen

Anthony Zaleski

Joseph Reeve

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

Non-toxic mutants of pathogenic gram-negative bacteria

This invention relates to purified sialic acid permease systems, and inhibitory agents of sialic acid permease systems.

Sialic acid permease system

The present invention is directed to sialytransferases, such as SiaA sialytransferases isolated from. Further provided herein are methods for producing sialylated lipooligosaccharides, vaccines, and host cells and systems for the production of sialylated lipooligosaccharides.

[object Object]

The present invention is directed to novel polypeptides, polynucleotides and vaccines for use againstcolonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.

Vaccine and compositions for the prevention and treatment of neisserial infections

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

The present invention provides a fast and efficient method for determining the three-dimensional conformation of a protein. The steps of the method of the invention include: 1) formation of physical distance constraints, e.g., forming intramolecular chemical crosslinks of known size between residues of a protein; 2) enriching the number of the molecules that have intramolecular chemical crosslinks in the reaction pool, e.g., using size separation to remove proteins with intermolecular bonds; 3) exposing the enriched reaction pool to a protease that cuts the protein at specific sites to produce peptide fragments; 4) measuring the size of the peptide fragments to determine linkage sites with a certain spatial relationship in the protein; and 5)interpreting the data produced to determine spatial geometry and protein structure based on the deduced spatial relationship of the linkage sites. The information is preferably analyzed with aid from a computer system, which can be used to generate and/or analyze distance constraints between amino acids.

Method of determining the three-dimensional shape of a macromolecule

Compositions and methods for making complex carbohydrates in a bacterial production cell are disclosed. The complex carbohydrates that can be made include oligosaccharides and polysaccharides of bacterial or mammalian origin.

Production of complex carbohydrates

Antigenic conjugates are provided which comprise a carrier protein covalently bonded to the conserved portion of a lipopolysaccharide of a gram negative bacteria, wherein the conserved portion of the lipopolysaccharide comprises the inner core and lipid A portions of the lipopolysaccharide, the conjugate eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria.

Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria

Exochelins can be used to prevent damage to living tissue from the formation or presence of the (.cndot.OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins as well as other applications of these materials in the treatment and diagnosis of disease in mammals.

Iron chelator and inhibitor of iron-mediated oxidant injury

Growing community of inventors

Berkeley, CA, United States of America

Bradford W Gibson